NovoCure Limited Profile Avatar - Palmy Investing

NovoCure Limited

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and G…

Medical - Instruments & Supplies
JE, Saint Helier [HQ]

Cash Flow Statements

11 Records · Starting from 2013
In Million USD. Margins, Growth Rates In %
Metric 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Operating Activities
Operating Cash Flow (OCF)
-52.00 -74.00 -99.00 -107.00 -33.00 -1.00 26.00 99.00 82.00 30.00 -73.00
Operating Cash (Net)
-52.00 -74.00 -99.00 -107.00 -33.00 -1.00 26.00 99.00 82.00 30.00 -73.00
Accounts Receivable
- - 1.00 -1.00 -6.00 -23.00 -4.00 -36.00 -30.00 5.00 2.00 29.00
Accounts Payable
5.00 - - 6.00 1.00 -1.00 9.00 16.00 25.00 27.00 14.00 14.00
Working Capital
- - - - - - - - - - - - - - - - - - - - - -
Investing Activities
Used Cash (Net)
10.00 -46.00 -115.00 12.00 6.00 -5.00 -51.00 -472.00 -144.00 -139.00 184.00
Capital Expenditure
-3.00 -2.00 -10.00 -17.00 -7.00 -6.00 -10.00 -14.00 -24.00 -21.00 -27.00
Purchases of Investments
- - -137.00 -208.00 -239.00 -104.00 -253.00 -461.00 -607.00 -1,078.00 -1,297.00 -1,003.00
Sale/Maturity of Investment
15.00 93.00 104.00 270.00 120.00 255.00 420.00 150.00 958.00 1,179.00 1,214.00
Property, Plant, Equipment (P&PE)
-3.00 -2.00 -10.00 -17.00 -7.00 -6.00 -10.00 -14.00 -24.00 -21.00 -27.00
Acquisitions (Net)
- - - - - - - - - - 3.00 41.00 457.00 120.00 118.00 -211.00
Other Investing Activities
-1.00 1.00 - - - - -1.00 -3.00 -41.00 -457.00 -120.00 -118.00 211.00
Financing Activities
Used Cash (Net)
-183.00 -2.00 -276.00 -75.00 -5.00 -69.00 -61.00 -440.00 -25.00 -15.00 -15.00
Debt Repayment
-58.00 - - - - - - - - -100.00 - - -150.00 - - - - - -
Dividends Paid
- - - - - - - - - - - - - - - - - - - - - -
Common Stock
- - - - 252 - - - - - - - - - - - - - - - -
Other Financing Activities
49.00 2.00 24.00 74.00 3.00 167.00 59.00 586.00 21.00 10.00 11.00
Cash Balances
Begin of Period
34.00 175.00 57.00 119.00 99.00 80.00 142.00 179.00 246.00 209.00 115.00
End of Period
175.00 57.00 119.00 99.00 78.00 142.00 179.00 246.00 209.00 115.00 242.00
Change
141.00 -118.00 61.00 -19.00 -21.00 62.00 36.00 66.00 -36.00 -93.00 126.00
Non-Cash Balances
Depreciation and Amortization
1.00 1.00 3.00 5.00 7.00 9.00 8.00 9.00 10.00 10.00 10.00
Stock Based Compensation
5.00 4.00 11.00 22.00 27.00 - - 52.00 75.00 94.00 106.00 115.00
Other
11.00 - - 1.00 - - - - 1.00 -2.00 3.00 3.00 -6.00 -23.00
Highlighted metrics
Free Cash Flow (FCF)
-56.00 -76.00 -110.00 -125.00 -40.00 -8.00 16.00 84.00 58.00 9.00 -100.00
Cash Conversion Cycle (CCC)
-300.00 -125.00 63.00 129.00 109.00 55.00 37.00 -2.00 -77.00 -101.00 -104.00
Invested Capital
- - - - - - - - - - - - - - - - - - - - - -
Other Operating Inflows/Outflows
End of NVCR's Analysis
CIK: 1645113 CUSIP: G6674U108 ISIN: JE00BYSS4X48 LEI: - UEI: -
Secondary Listings
NVCR has no secondary listings inside our databases.